The role of HER2 in modulating the efficacy of CDK4/6 inhibitor combined with endocrine therapy in HR+/HER2-low breast cancer was assessed by silencing HER2 in HR+/HER2-low breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.